ATTRACTION-3

NCT02569242 📎

Regimen

Experimental
nivolumab
Control
investigator-choice chemotherapy (paclitaxel or docetaxel)

Population

Unresectable advanced or recurrent ESCC refractory or intolerant to prior fluoropyrimidine plus platinum chemotherapy, regardless of PD-L1

Key finding

mOS 10.9 vs 8.4 mo (HR 0.77, 95% CI 0.62-0.96, p=0.019); grade 3-4 TRAE 18% vs 63% — IO toxicity much lower than taxane

Source: PMID 31582355

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.66)